Ország: Kanada
Nyelv: angol
Forrás: Health Canada
METHOCARBAMOL; IBUPROFEN
VITA HEALTH PRODUCTS INC
M03BA53
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
500MG; 200MG
TABLET
METHOCARBAMOL 500MG; IBUPROFEN 200MG
ORAL
18/40
OTC
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0248961001; AHFS:
APPROVED
2014-03-11
Page 1 of 41 PRODUCT MONOGRAPH MUSCLE AND BACK PAIN PLATINUM RELIEF Methocarbamol and Ibuprofen Caplets 500mg/200mg Muscle Relaxant/Analgesic VITA HEALTH PRODUCTS INC. Date of Preparation: 150 Beghin Avenue March 4, 2014 Winnipeg, MB R2J 3W2 Date of Revision: December 2, 2019 Control Number 231400 Page 2 of 41 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION..........................................................3 SUMMARY PRODUCT INFORMATION ...................................................................................3 INDICATIONS AND CLINICAL USE..........................................................................................3 CONTRAINDICATIONS ..............................................................................................................3 ADVERSE REACTIONS..............................................................................................................11 DRUG INTERACTIONS..............................................................................................................13 DOSAGE AND ADMINISTRATION..........................................................................................16 OVERDOSAGE ...........................................................................................................................16 ACTION AND CLINICAL PHARMACOLOGY .......................................................................18 STORAGE AND STABILITY......................................................................................................20 SPECIAL HANDLING INSTRUCTIONS ..................................................................................20 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................................21 PART II: SCIENTIFIC INFORMATION................................................................................22 PHARMACEUTICAL INFORMATION......................................................................................22 CLINICAL TRIALS.................................................. Olvassa el a teljes dokumentumot